BR9806330A - New use of the group of pharmaceutical formulations, known as antidepressant drugs, for the new use of premature ejaculation treatment - Google Patents

New use of the group of pharmaceutical formulations, known as antidepressant drugs, for the new use of premature ejaculation treatment

Info

Publication number
BR9806330A
BR9806330A BR9806330-8A BR9806330A BR9806330A BR 9806330 A BR9806330 A BR 9806330A BR 9806330 A BR9806330 A BR 9806330A BR 9806330 A BR9806330 A BR 9806330A
Authority
BR
Brazil
Prior art keywords
treatment
fluoxetine
premature ejaculation
group
ejaculation
Prior art date
Application number
BR9806330-8A
Other languages
Portuguese (pt)
Inventor
Edson Claro Do Nascimento
Original Assignee
Edson Claro Do Nascimento Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edson Claro Do Nascimento Dr filed Critical Edson Claro Do Nascimento Dr
Priority to BR9806330-8A priority Critical patent/BR9806330A/en
Publication of BR9806330A publication Critical patent/BR9806330A/en

Links

Abstract

Patente de Invenção novo uso do grupo de formulações farmacêuticas, conhecidos como drogas antidepressivas, para o novo uso do tratamento da Ejaculação Precoce, tais como: dos grupos IMAO, tricíclicos, inibidor seletivo da recaptação da Serotonina, inibidores mistos da recaptação de Serotonina e Noradrenalina, bloqueadores da recaptação da Noradrenalina e da Dopamina e moduladores adrenérgicos, para tratamento da Ejaculação Precoce. Para este invento, foi usado o efeito colateral, que é retardo da ejaculação, em indivíduos normais, chegando até a anorgasmia, e aplicou-se para os ejaculadores precoces, obtendo sucesso no tratamento, ou seja regularizando o tempo de ejaculação do indivíduo. Observa-se, conforme segue abaixo, resumos de trabalhos científicos, realizados por minha pessoa, com determinado tipo de droga, que objetivam o mesmo mecanismo, ou seja inibir a recaptação de Serotonina, ou alterar a transmissão dopaminérgica, enfim drogas que de alguma maneira, consegue controlar o disparo ejaculatório. Tratamento da Ejaculação Precoce: Fluoxenite e Terapia Sexual - Estudo Comparativo Autor: Edson Claro do Nascimento - Mogi das Cruzes - Br. Foram avaliados 529 pacientes com Ejaculação Precoce (E.P.), dividiu-se em 3 grupos por faixa etária: 1) Grupo I: de 21 a 25 anos; 2) Grupo II: de 25 a 45 anos (Idade média 35 anos); Grupo III: > de 45 anos. Preconizou-se Terapia Sexual (T.S.), n=96, como tratamento no grupo controle, para alguns pacientes de todos os grupos G I; GII; GIII e observou-se os resultados. Separou-se outra população destes grupos e tratou-se com T.S + Fluoxetine (Fluox)e um outro grupo de pacientes foram tratados somente com Fluoxetina. Resultados: Só com a terapia Sexual, o sucesso foi de 45,83%, sendo que dos 96 E.P. 44 tiveram sucesso; 14 abandonaram o tratamento e em 38 ejaculadores pre-coces tratados com Terapia Sexual ocorreu retorno dos sintomas. Este tratamento foi de 3 meses até 1 ano. O maior retorno dos sintomas foi no Grupo II (I. M. 35 anos). Nos grupos I; II; e III ao serem tratados com T.SX. e FLX (20 mg/d) ou só com FLX (20mg/d) a melhora da E.P. foi praticamente 100% dos 433 E.P., sem retorno dos sintomas, com "follow up" de 1 ano. O início do controle ejaculatório, com Fluox foi em média 10 dias, usado durante 40 a 60 dias, na dose média de 20 mg/d. Não houve abandono do tratamento neste grupo. A T.SX. foi até 60 dias. Não teve diferença significativa entre os grupos T.SX. + FLX e só com o uso do Fluoxetine, o controle ejaculatório foi por volta de 100%, mas houve diferença significativa, quanto ao grupo controle que recebera tratamento só com Terapia sexual. Não observou-se casos de impotência, apenas diminuição do número de intromissões, da freq³ência e da ansiedade, com melhora da qualidade total da relação com suas parceiras, bem como melhora no aspecto da relação social; ambiente de trabalho, enfim melhora geral. Neste estudo apenas 5 pacientes tratados com fluoxetina apresentaram como efeito colateral, desassossego muscular, o qual desapareceu em 15 dias após a suspensão da droga. Não foi elucidado se foi devido a interrupção do tratamento abruptamente, por parte dos pacientes, ou se foi realmente dependente da droga. Houveram 16 casos de insónia que cederam com associação de Diazepan 5 mg à noite. Aspecto interessante é que a Fluoxetina é um antidepressivo seletivo de recaptação de Serotonina e de alguma forma, também apresentou ação ansiolítica, relatado pela maioria dos pacientes que a usaram, mas que não causou sonolência. Nascimento, refere que o tratamento da Ejaculação Precoce com Cloridrato de Imipramina, apresentou vários efeitos colaterais e os sintomas retornavam com a suspensão do medicamento, o que não ocorreu com a Fluoxetina. Outros fatores positivos do tratamento medicamentoso da Ejaculação Precoce com Fluoxetina: 1) Não necessidade da parceria ou parceiras sub rogadas, para a colabora-ção na Terapia Sexual (Masther's & Johnson's); o pouco tempo para a resolução do sintoma e praticamente ausência de efeitos colaterais. Portanto acredito que a Fluoxetina, é uma droga importante no tratamento da Ejaculação Precose. Não Publicado Disfunções Sexuais X Funções X Stress X Fluoxetina - Estudo Epidemiológico - Projeções da Baixada Santista (S.P.) para área Metropolitana de S. Paulo (AMSP); restante do Estado de São Paulo (RESP) e Brasil - BR - 1991. Autor: Dr. Edson Claro do Nascimento - Mogi das Cruzes - SP - Brasil - Br. Realizada entrevista a 1940 pessoas, sendo 1090 mulheres (M) e 850 homens (H), Detectou-se 20,18 % de D. S. Feminina (D.S.F.) e 12,94 % de D.S. Masculina, D.Erétil foi de 0,58% do total das D.S.M e DSF. Resultados: AM: 606.495 DSM e 646.494 DSf; RESP: 1.286.423 DSM e 1.307.073 DSF; BR = 5.718.349 DSM e 6.043.340 DSF, com pelo menos uma D.S., Total: 11.761.689 Brasileiros com D. Sexuais. Funções Extressantes: 72, 72 % dos homens = Ejaculação Precoce (E. P. ) e 50 % das mulheres = Anorgásmicas. Outro dado importante é que 81,81 % dos sujeitos deste trabalho, independente do sexo e do tipo da D.S., apresentaram de 1 a 20 queixas clínicas psicossomáticas. O tratamento medicamentoso com Fluoxetine (IRSS) para Ejaculação Precoce e Disfunção Erétil (Stress), tem demonstrado ótimos resultados para D.S.M., mas não para as femininas. An-siolíticos e Terapia Sexual, podem ajudar em muito tratamento das mulheres com D.Sexuais femininas (Nascimento, Edson, C.; 1991; SP; Brasil) - Não Publicado - Formulações farmacêuticas apropriadas para fabricação de comprimidos dispersíveis por compressão direta, poderão compreender, além dos principios ativos os excipientes e coadjuvantes apropriados selecionados dentre desintegrantes, diluentes, lubrificantes, anti-aderentes, adoçantes, aromatizantes e opcionalmente colorantes. A exemplo, já foi observado em pacientes usuários com depressão, ou não, mas com Ejaculação Precoce presente, foi realizado tratamento com Fluoxetina, e outros medicamentos dos grupos acima citados obtendo sucesso. O novo uso do cloridrato de Fluoxetina para o tratamento da Ejaculação Precoce, no homem adulto, poderá ser realizado na dosagem de 20 a 60 mg/d, as <MU>10 h da manhã<MV>. A importância do invento do novo uso do grupo de formulações farmacêuticas, conhecidos como drogas antidepressivas, para o novo uso do tratamento da Ejaculação Precoce. Novo uso terapeutico dos antidepressivos e inibidores da re-captação da Serotonina, está na grande incidência que esta disfunção sexual que acomete os homens adultos, com várias repercurssões sexo-sociais. Seu mecanismo parece inibir a recaptação da Serotonina, nas sinápses do Sistema Nervoso Central e Periférico, basicamente no Sistema Límbico Hipotalâmico, bem como interagindo com receptores 5-HT do tronco encefálico e medular. A presença da Serotonina em maiores concentrações na fenda sináptica, au-menta o tempo em que a neurotransmissão dopaminérgica ocorre, resultando em um aumento da concentração de dopamina e outras possíveis substâncias e subprodutos formados, aumentando desta forma, o limiar do potencial de ação do reflexo orgástico, aumentando em última análise o tempo de controle voluntário e involuntário da ejaculação, produzindo finalmente maior tempo de controle da ejaculação no homem.Invention Patent new use of the group of pharmaceutical formulations, known as antidepressant drugs, for the new use of the treatment of Premature Ejaculation, such as: of the IMAO groups, tricyclic, selective inhibitor of the reuptake of Serotonin, mixed inhibitors of the reuptake of Serotonin and Noradrenaline , Noradrenaline and Dopamine reuptake blockers and adrenergic modulators for the treatment of premature ejaculation. For this invention, the side effect, which is delayed ejaculation, in normal individuals, reaching anorgasmia, was used and applied to early ejaculators, obtaining success in the treatment, that is, regularizing the individual's ejaculation time. It is observed, as follows, summaries of scientific works, carried out by me, with a certain type of drug, which aim at the same mechanism, that is, to inhibit the reuptake of Serotonin, or to alter the dopaminergic transmission, finally drugs that in some way , manages to control ejaculatory firing. Treatment of Premature Ejaculation: Fluoxenitis and Sex Therapy - Comparative Study Author: Edson Claro do Nascimento - Mogi das Cruzes - Br. 529 patients with Premature Ejaculation (EP) were evaluated, divided into 3 groups by age group: 1) Group I : from 21 to 25 years; 2) Group II: from 25 to 45 years (mean age 35 years); Group III:> 45 years old. Sex Therapy (T.S.), n = 96, was recommended as treatment in the control group, for some patients of all groups G I; GII; GIII and the results were observed. Another population was separated from these groups and treated with T.S + Fluoxetine (Fluox) and another group of patients were treated only with Fluoxetine. Results: Only with Sex therapy, the success was 45.83%, and of the 96 E.P. 44 were successful; 14 abandoned treatment and in 38 precocious ejaculators treated with sexual therapy, symptoms returned. This treatment was from 3 months to 1 year. The greatest return of symptoms was in Group II (I. M. 35 years old). In groups I; II; and III when treated with T.SX. and FLX (20 mg / d) or only with FLX (20 mg / d), the improvement of the EP was practically 100% of the 433 EP, with no return of symptoms, with a follow-up of 1 year. The onset of ejaculatory control with Fluox was on average 10 days, used for 40 to 60 days, at an average dose of 20 mg / d. There was no abandonment of treatment in this group. T.SX. it was up to 60 days. There was no significant difference between the T.SX groups. + FLX and only with the use of Fluoxetine, the ejaculatory control was around 100%, but there was a significant difference, as for the control group that received treatment only with Sex Therapy. There were no cases of impotence, only a decrease in the number of intrusions, frequency and anxiety, with an improvement in the total quality of the relationship with their partners, as well as an improvement in the aspect of the social relationship; work environment, in short, general improvement. In this study, only 5 patients treated with fluoxetine presented muscle uneasiness as a side effect, which disappeared in 15 days after the drug was discontinued. It has not been clarified whether it was due to abrupt interruption of treatment by the patients, or whether it was really dependent on the drug. There were 16 cases of insomnia that subsided with Diazepan 5 mg at night. Interesting aspect is that Fluoxetine is a selective serotonin reuptake antidepressant and somehow, it also showed anxiolytic action, reported by most patients who used it, but did not cause drowsiness. Nascimento, says that the treatment of Premature Ejaculation with Imipramine Hydrochloride, had several side effects and the symptoms returned with the suspension of the drug, which did not occur with Fluoxetine. Other positive factors of the drug treatment of Premature Ejaculation with Fluoxetine: 1) No need for partnership or subrogated partners, for collaboration in Sex Therapy (Masther's &Johnson's); the short time for symptom resolution and practically no side effects. So I believe that Fluoxetine is an important drug in the treatment of Premature Ejaculation. Not Published Sexual Dysfunctions X Functions X Stress X Fluoxetine - Epidemiological Study - Projections of Baixada Santista (S.P.) for the Metropolitan Area of S. Paulo (AMSP); rest of the State of São Paulo (RESP) and Brazil - BR - 1991. Author: Dr. Edson Claro do Nascimento - Mogi das Cruzes - SP - Brazil - Br. Interview conducted with 1940 people, 1090 women (M) and 850 men (H), 20.18% of female DS (DSF) and 12.94% of female DS were detected Male, D.Erétil was 0.58% of the total D.S.M and DSF. Results: AM: 606,495 DSM and 646,494 DSf; RESP: 1,286,423 DSM and 1,307,073 DSF; BR = 5,718,349 DSM and 6,043,340 DSF, with at least one D.S., Total: 11,761,689 Brazilians with D. Sexual. Extressive Functions: 72, 72% of men = Premature Ejaculation (E.P.) and 50% of women = Anorgasmic. Another important fact is that 81.81% of the subjects in this study, regardless of gender and type of D.S., had 1 to 20 psychosomatic clinical complaints. Drug treatment with Fluoxetine (IRSS) for Premature Ejaculation and Erectile Dysfunction (Stress), has shown excellent results for D.S.M., but not for women. Anxiolytics and Sex Therapy, can help a lot in the treatment of women with D.Sexual women (Nascimento, Edson, C .; 1991; SP; Brazil) - Not Published - Pharmaceutical formulations suitable for the manufacture of dispersible tablets by direct compression, may understand, in addition to the active ingredients, the appropriate excipients and adjuvants selected from disintegrants, diluents, lubricants, anti-adherents, sweeteners, flavorings and optionally colors. For example, it has already been observed in patients with depression, or not, but with Premature Ejaculation present, treatment with Fluoxetine, and other drugs from the groups mentioned above was successful. The new use of Fluoxetine hydrochloride for the treatment of Premature Ejaculation, in adult men, can be performed at a dosage of 20 to 60 mg / d, at <MU> 10 am in the morning <MV>. The importance of the invention of the new use of the group of pharmaceutical formulations, known as antidepressant drugs, for the new use of the treatment of Premature Ejaculation. New therapeutic use of antidepressants and serotonin re-uptake inhibitors is due to the great incidence that this sexual dysfunction affects adult men, with various sex-social repercussions. Its mechanism seems to inhibit the reuptake of Serotonin, in synapses of the Central and Peripheral Nervous System, basically in the Limbic Hypothalamic System, as well as interacting with 5-HT receptors in the brain and spinal cord. The presence of Serotonin in higher concentrations in the synaptic cleft increases the time in which dopaminergic neurotransmission occurs, resulting in an increase in the concentration of dopamine and other possible substances and by-products formed, thus increasing the threshold of the action potential of orgasmic reflex, ultimately increasing the time of voluntary and involuntary control of ejaculation, ultimately producing longer time for ejaculation control in men.

BR9806330-8A 1998-08-26 1998-08-26 New use of the group of pharmaceutical formulations, known as antidepressant drugs, for the new use of premature ejaculation treatment BR9806330A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR9806330-8A BR9806330A (en) 1998-08-26 1998-08-26 New use of the group of pharmaceutical formulations, known as antidepressant drugs, for the new use of premature ejaculation treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR9806330-8A BR9806330A (en) 1998-08-26 1998-08-26 New use of the group of pharmaceutical formulations, known as antidepressant drugs, for the new use of premature ejaculation treatment

Publications (1)

Publication Number Publication Date
BR9806330A true BR9806330A (en) 2000-09-12

Family

ID=4071372

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9806330-8A BR9806330A (en) 1998-08-26 1998-08-26 New use of the group of pharmaceutical formulations, known as antidepressant drugs, for the new use of premature ejaculation treatment

Country Status (1)

Country Link
BR (1) BR9806330A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002041883A2 (en) * 2000-11-21 2002-05-30 Vivus, Inc. As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002041883A2 (en) * 2000-11-21 2002-05-30 Vivus, Inc. As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
WO2002041883A3 (en) * 2000-11-21 2003-12-18 Vivus Inc As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
US6946141B2 (en) 2000-11-21 2005-09-20 Vivus, Inc. As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation

Similar Documents

Publication Publication Date Title
Meston et al. Psychoactive drugs and human sexual behavior: the role of serotonergic activity
Masters et al. Melatonin, the hormone of darkness: from sleep promotion to ebola treatment
Segraves et al. Clomipramine versus placebo in the treatment of premature ejaculation: a pilot study
Vázquez et al. “Panic attacks” in Parkinson's disease: A long‐term complication of levodopatherapy
Sloan et al. Fluoxetine as a treatment for emotional lability after brain injury
JPH06508836A (en) Methods and compositions for the treatment of emesis, nausea and other disorders using optically pure R(+) ondansetron
PL181802B1 (en) Treatment of sclerosis multiplex (sm) an dother demyelination states
Pages et al. Use of anticonvulsants in benzodiazepine withdrawal
Lauerma Successful treatment of citalopram‐induced anorgasmia by cyproheptadine
Alamo et al. Tianeptine, an atypical pharmacological approach to depression
Nolen et al. L-5HTP in depression resistant to re-uptake inhibitors: an open comparative study with tranylcypromine
Nutt et al. Adult night terrors and paroxetine
Gul et al. Current and emerging treatment options for premature ejaculation
HUP0302436A2 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
de Azevedo et al. Treatment of tinnitus with acamprosate
Sandyk et al. Opiates in the restless legs syndrome
Toyofuku Efficacy of milnacipran for glossodynia patients
BR9806330A (en) New use of the group of pharmaceutical formulations, known as antidepressant drugs, for the new use of premature ejaculation treatment
Piediferro et al. Premature ejaculation. 3. Therapy
NO312814B1 (en) Use of melatonin in the manufacture of a drug for the treatment of patients suffering from drug dependence
Wood et al. Drug plasma levels and platelet 5‐HT uptake inhibition during long‐term treatment with fluvoxamine or lithium in patients with affective disorders.
BR9806331A (en) New use of the substance fluoxetine hydrochloride, as a new therapeutic indication for the treatment of premature ejaculation
Dieci et al. Resolution of citalopram sexual adverse effects with low dose of cariprazine: a case report
Kerbeshian et al. Tourette syndrome and recurrent paraphilic masturbatory fantasy
Gelenberg et al. Sexual side effects of antidepressant drugs

Legal Events

Date Code Title Description
B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI

B12B Appeal: appeal against refusal